eTheRNA, a spun out of Belgium’s Vrije Universiteit Brussel, is a clinical-stage biotech company developing innovative immuno-oncology therapies based on its unique APC-activating messenger RNA platform.
eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases.
eTheRNA was founded in 2013 by Kris Thielemans. The company is headquartered in Niel, Antwerpen, Belgium.
eTheRNA has created, eTheRNA’s TriMix platform, a core differentiating component in the Company’s product programs and comprises three mRNAs encoding proteins that act together to significantly increase immune responses.
TriMix has demonstrated broad application across major cancer types, both preclinically and clinically, offering the prospect of therapeutic vaccines and localised tumor treatments acting synergistically with standard of care treatments. To facilitate its product development activities eTheRNA has developed a proprietary lipid nanoparticle (LNP) platform to enable intravenous delivery of various (neo)antigens.
eTheRNA is backed by LSP, PMV, Boehringer Ingelheim Venture Fund, Fund+, Omega Fund, Grand Decade, BNP Paribas Fortis Private Equity and others. The company raised €34M ($38M) in Series B round on June 16, 2020. This brings eTheRNA's total funding to €59M to date.